• Wondering if Catalyst Pharmaceuticals at around US$24.69 still offers value or if most of the opportunity is already reflected in the price? This breakdown is designed to help you frame that question clearly.
• The stock has returned 1.8% over the last week, 3.2% over the last month, 6.7% year to date and 2.4% over the past year, with a very large 5 year return that points to a multi year rerating.
• Recent coverage has focused on Catalyst Pharmaceuticals as an established rare disease player with a growing product portfolio and ongoing interest around its role in neurology and orphan drug markets. That context helps explain why shorter term moves may matter less to some investors than the multi year story.
• On Simply Wall St's 6 point valuation checklist, Catalyst Pharmaceuticals scores a full 6 out of 6. Next up is a look at how different valuation methods stack up for the stock and, later in the article, a way to tie those numbers back to the bigger picture of what the business might be worth over time.

Approach 1: Catalyst Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those back to a single present value per share.

For Catalyst Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on last twelve month free cash flow of about $129.4 million. Analyst projections and Simply Wall St extrapolations suggest free cash flow reaching $384.8 million in 2035, with interim projections such as $221 million in 2026 and $340 million in 2030, all in $ and then discounted back to today.

Combining those discounted cash flows gives an estimated intrinsic value of US$63.46 per share. Compared to a recent share price of around US$24.69, the DCF output implies an intrinsic discount of 61.1%, which indicates the stock is trading materially below this cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Catalyst Pharmaceuticals is undervalued by 61.1%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Catalyst Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to relate what you pay per share to the earnings that each share generates. Investors typically look for a P/E that lines up with their expectations for future growth and risk, with higher growth or lower perceived risk often supporting a higher "normal" or "fair" P/E level.

Catalyst Pharmaceuticals currently trades on a P/E of 14.07x. That sits below the Biotechs industry average P/E of 15.25x and well below the peer average of 30.05x. On the surface, that suggests the market is assigning a lower earnings multiple to Catalyst than to many peers in the same space.

Simply Wall St's Fair Ratio for Catalyst comes in at 14.89x. This is a proprietary estimate of what a reasonable P/E might be, given factors such as earnings growth, industry, profit margins, market cap and risk profile. Because it adjusts for these company specific features, the Fair Ratio can be more informative than a simple comparison with raw industry or peer averages. With the actual P/E of 14.07x sitting below the 14.89x Fair Ratio, the shares screen as moderately undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Catalyst Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced as a simple way for you to attach a clear story about Catalyst Pharmaceuticals to the numbers you are using for fair value, future revenue, earnings and margins. You can then link that story to a forecast and a fair value on Simply Wall St's Community page, and compare that fair value to the current price to decide if the stock fits your plan. The Narrative itself automatically refreshes when new information such as news or earnings is added.

For example, one investor on the platform might build a Narrative close to the higher analyst price target of US$40, focusing on broader patient access, AGAMREE's launch and the potential for continued earnings growth. Another might align with the lower target of US$31, centering their story on reliance on a few key drugs, generic competition, litigation outcomes and rising expenses. Both can clearly see how their assumptions translate into different fair values for the same shares.

Do you think there's more to the story for Catalyst Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.